Showing 131-140 of 9931 results for "".
Keloids: To Cut or Not to Cut
https://practicaldermatology.com/topics/skin-cancer-photoprotection/keloids-to-cut-or-not-to-cut/19987/When treating keloids, ask patients what they want to achieve. Are they hoping to decrease itch or pain? Do they want to flatten or soften the appearance of a keloid? Hilary Baldwin, MD reviews her approach to deciding whether to remove a keloid surgically as well as other treatment options. Plus, sDerm Insider: Navigating Office Politics
https://practicaldermatology.com/topics/practice-management/derm-insider-navigating-office-politics/18993/In this edition of Derm Insider, host Neal Bhatia, MD speaks with practice management experts about the complex inner workings of an office environment, as well as the role of physicians in managing precarious situations regarding employees. Offering advice for maneuvering these situations, guests SLight & Bright: A new treatment to illuminate your practice
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/light-bright-a-new-treatment-to-illuminate-your-practice/19746/Join Matthew Mahlberg, MD as he introduces the new Light & Bright treatment. Using the patented Ellipse IPL and Frax 1550 technologies on the Nordlys system, the Light & Bright treatment reduces pigmentation & redness and improves textural irregularities. Hear the results of a clinical sDupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sActinic Keratosis: Therapy Overview
https://practicaldermatology.com/topics/skin-cancer-photoprotection/actinic-keratosis-therapy-overview/19732/Joel Cohen, MD interviews George Martin, MD about the latest developments in actinic keratosis. Dr. Martin said he is eagerly awaiting regulatory review of tirbanibulin, which showed promising results in clinical trials. The two also discuss practical tips and nuances of using 5FU in practice. *Be sBimekizumab-bkzx Journal Scan: 4 Clinical Trials
https://practicaldermatology.com/topics/digital-supplement/bimekizumab-bkzx-journal-scan-4-clinical-trials/24128/Speed, depth, and durability from the first dual IL-17A/F inhibitor for the treatment of moderate to severe plaque psoriasis.Rethinking Sebum and Its Role in Acne
https://practicaldermatology.com/topics/acne-rosacea/quality-over-quantity-rethinking-sebum-and-its-role-in-acne/23736/In follow-up to a recent column about the function of sebaceous glands, here’s a closer look at sebum itself.What’s Really in a “Collagen” Supplement?
https://practicaldermatology.com/youngmd-connect/resident-resource-center/whats-really-in-a-collagen-supplement/23579/Concerns about lack of transparency of sourcing, potential for allergic reactions, and reports of contamination have been associated with collagen supplements.Mechanisms for Food Allergy Initiation by Skin Pre-disposed to Atopic Dermatitis
https://practicaldermatology.com/issues/may-june-2025/mechanisms-for-food-allergy-initiation-by-skin-pre-disposed-to-atopic-dermatitis/35922/In this research report, we highlight a 2024 study by Gao et al. investigating the mechanisms underlying food allergy initiation in neonates susceptible to atopic dermatitis (AD).The Value of Radiation as an Option for BCC and SCC
https://practicaldermatology.com/issues/may-june-2025/the-value-of-radiation-as-an-option-for-bcc-and-scc/35919/The Skin Cancer Foundation calls Mohs micrographic surgery the gold standard for treating basal cell carcinomas and squamous cell carcinomas.